Compare Appian Corp (APPN) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Appian Corp vs Tilray Brands Inc — how do they compare? Appian Corp trades at $25.44 (market cap $1.86B), while Tilray Brands Inc trades at $4.5 (market cap $544.44M). The key difference: Appian Corp is far larger — about 3.4× Tilray Brands Inc's market cap, and Appian Corp is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| APPN | TLRY | |
|---|---|---|
Market Cap | $1.86B | $544.44M |
Sector | Technology | Health |
52-Week High | $45.64 | $21.00 |
52-Week Low | $18.72 | $4.31 |
Enterprise Value | $1.95B | $641.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.
The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.
TLRY trades at $4.42, up 0.68% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows low valuation ratios (P/S 0.55, P/B 0.35) but deep losses (net margin -156.67%) and negative cash flow from operations. Recent news highlights expansion in medical cannabis and new product launches, yet earnings misses and high debt-to-asset ratios signal ongoing challenges.
Outlook remains uncertain with profitability elusive; growth via acquisitions adds scale but not earnings. Analyst consensus is cautious (25% buy, 65% hold), reflecting skepticism about near-term turnaround. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
